Surgical Endoscopy

, Volume 24, Issue 4, pp 961–963

Totally laparoscopic vs. laparoscopically assisted distal gastrectomy for gastric cancer

Letter

References

  1. 1.
    Kim W, Song KY, Lee HJ et al (2008) The impact of co morbidity on surgical outcomes in laparoscopy-assisted distal gastrectomy: a retrospective analysis of multicenter results. Ann Surg 248(5):793–799CrossRefPubMedGoogle Scholar
  2. 2.
    Kim YW, Baik YH, Yun YH et al (2008) Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 248(5):721–727CrossRefPubMedGoogle Scholar
  3. 3.
    Ikeda O, Sakaguchi Y, Aoki Y et al (2009) Advantages of totally laparoscopic distal gastrectomy over laparoscopically assisted distal gastrectomy for gastric cancer. Surg Endosc [Epub ahead of print]Google Scholar
  4. 4.
    Strong VE, Devaud N, Allen PJ et al (2009) Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case–control study. Ann Surg Oncol 16(6):1507–1513CrossRefPubMedGoogle Scholar
  5. 5.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMedGoogle Scholar
  6. 6.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMedGoogle Scholar
  7. 7.
    Kappas AM et al (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830CrossRefPubMedGoogle Scholar
  8. 8.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMedGoogle Scholar
  9. 9.
    Kappas AM, Fatouros M et al (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727–730CrossRefPubMedGoogle Scholar
  10. 10.
    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas-Couchell S (1990) A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol 116:307–311CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129CrossRefPubMedGoogle Scholar
  14. 14.
    Liakakos T, Roukos DH (2008) More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960CrossRefPubMedGoogle Scholar
  15. 15.
    Briasoulis E, Fatouros M et al (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedCrossRefGoogle Scholar
  16. 16.
    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMedGoogle Scholar
  17. 17.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMedGoogle Scholar
  18. 18.
    Ziogas D, Baltogiannis G, Fatouros M et al (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715CrossRefPubMedGoogle Scholar
  19. 19.
    Fatouros M et al (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33CrossRefPubMedGoogle Scholar
  20. 20.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):1555–1556PubMedGoogle Scholar
  21. 21.
    Agnantis NJ et al (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMedGoogle Scholar
  24. 24.
    Fatouros M et al (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745CrossRefPubMedGoogle Scholar
  25. 25.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362–1363CrossRefPubMedGoogle Scholar
  27. 27.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597CrossRefPubMedGoogle Scholar
  29. 29.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361CrossRefPubMedGoogle Scholar
  30. 30.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMedGoogle Scholar
  32. 32.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197CrossRefPubMedGoogle Scholar
  33. 33.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMedGoogle Scholar
  34. 34.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMedGoogle Scholar
  35. 35.
    Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMedGoogle Scholar
  36. 36.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMedGoogle Scholar
  37. 37.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMedGoogle Scholar
  38. 38.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Surgery, Chirurgische KlinikSt. ElisabethenkrankenhausFrankfurtGermany

Personalised recommendations